Ernexa therapeutics inc.ERNA.US Overview

US StockHealthcare

(No presentation for ERNA)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ERNA Overall Performance

ERNA AI Analysis & Strategy

ERNA Recent Performance

7.77%

Ernexa therapeutics inc.

0.29%

Avg of Sector

0.14%

S&P500

ERNA PowerScanner

ERNA Key Information

ERNA Valuation Metrics

ERNA Earnings Table

ERNA Profile

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.